In a year that has seen significant changes throughout the generics and biosimilars industry ranking, the top 10 has welcomed two Indian off-patent leaders. Meanwhile, companies lower down our ranking have enjoyed mixed fortunes, leading to a number of significant movements in this year’s Generics Bulletin Top 50.

Plus deals involving Fujimoto/Egetis, Chugai/Cheplapharm, Celest/Senti, Shionogi/Apnimed, Jiangsu Hengrui/Merck KGaA, Jiangsu Hengrui/Elevar, Sun/Zydus, C4U/Healiva, Shanghai Henlius/Intas, Ono/Turbine, EpimAB/Almirall and Alar/Indivior.

Dr Reddy’s, rumored to be in the fray for Biogen’s biosimilars business, among other potential high-profile transactions, retains an appetite for ‘complementary’ deals, though management indicates it isn’t pursuing ‘transformative’ buys. The company continues to tap Chinese firms for innovative assets.

Dr Reddy’s, rumored to be in the fray for Biogen’s biosimilars business, among other potential high-profile transactions, retains an appetite for ‘complementary’ deals, though management indicates it isn’t pursuing ‘transformative’ buys. The company continues to tap Chinese firms for innovative assets.